Clinical Trials | August 28, 2023
Zydus to present on ZYIL1 at the International Congress of Parkinson's Disease and Movement Disorders
In Phase I studies, ZYIL1 was found to be safe and well-tolerated in human volunteers
In Phase I studies, ZYIL1 was found to be safe and well-tolerated in human volunteers
KNISS has established a solid foundation of trust in the customers' minds, delivering high quality Products uncompromisingly.
First PARP inhibitor approved in Japan to demonstrate clinically meaningful benefits in combination with a new hormonal agent
Centre aims to train surgeons and other healthcare professionals from India and Southeast Asia in robotic-assisted surgery
Rs. 64000 crores are being invested across the 750 districts of India, to create a more resilient healthcare system in the country
Eris Lifesciences enters into term loan agreement with Citi Bank
Jupiter has filed its draft herring prospectus (DRHP) with the market regulator in May this year, to float its IPO
The deal represents a total transaction value of up to $36 million with an initial upfront consideration of $14 million
Oteseconazole Capsules were found to be safe and more effective than fluconazole
With India supplying around 60% of the world's vaccine needs and 20-22% of generic exports, the country is dedicated to providing affordable, high-quality drugs and contribute to global accessibility
Subscribe To Our Newsletter & Stay Updated
